Log in
NYSEAMERICAN:TRXC

TransEnterix Stock Forecast, Price & News

$0.35
+0.01 (+2.93 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.33
Now: $0.35
$0.36
50-Day Range N/A
52-Week Range
$0.28
Now: $0.35
$8.45
Volume1.22 million shs
Average Volume3.58 million shs
Market Capitalization$35.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Read More
TransEnterix logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$35.09 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$0.35
+0.01 (+2.93 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of TransEnterix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for TransEnterix
.

When is TransEnterix's next earnings date?

TransEnterix is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for TransEnterix
.

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) issued its earnings results on Wednesday, August, 5th. The medical instruments supplier reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.17. The medical instruments supplier earned $0.66 million during the quarter, compared to analysts' expectations of $0.29 million.
View TransEnterix's earnings history
.

Are investors shorting TransEnterix?

TransEnterix saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 4,860,000 shares, an increase of 23.7% from the August 15th total of 3,930,000 shares. Based on an average daily volume of 5,850,000 shares, the short-interest ratio is presently 0.8 days. Currently, 5.3% of the shares of the stock are sold short.
View TransEnterix's Short Interest
.

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), Actinium Pharmaceuticals (ATNM), XOMA (XOMA), Geron (GERN), Opko Health (OPK), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Who are TransEnterix's key executives?

TransEnterix's management team includes the following people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

Who are TransEnterix's major shareholders?

TransEnterix's stock is owned by many different institutional and retail investors. Top institutional investors include Bridgeway Capital Management Inc. (0.28%), Bank of America Corp DE (0.12%), Jane Street Group LLC (0.06%), Verition Fund Management LLC (0.11%) and AQR Capital Management LLC (0.05%). Company insiders that own TransEnterix stock include Andrea Biffi, Joseph P Slattery, William N Starling Jr and William N Starling, Jr.
View institutional ownership trends for TransEnterix
.

Which major investors are buying TransEnterix stock?

TRXC stock was purchased by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Verition Fund Management LLC, AQR Capital Management LLC, Bank of America Corp DE, and Jane Street Group LLC.
View insider buying and selling activity for TransEnterix
.

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $0.35.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $35.09 million.

What is TransEnterix's official website?

The official website for TransEnterix is www.transenterix.com.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.